AR087748A1 - Metodo para mejorar la terapia de enfermedades autoinmunes tales como artritis reumatoide - Google Patents
Metodo para mejorar la terapia de enfermedades autoinmunes tales como artritis reumatoideInfo
- Publication number
- AR087748A1 AR087748A1 ARP120103216A ARP120103216A AR087748A1 AR 087748 A1 AR087748 A1 AR 087748A1 AR P120103216 A ARP120103216 A AR P120103216A AR P120103216 A ARP120103216 A AR P120103216A AR 087748 A1 AR087748 A1 AR 087748A1
- Authority
- AR
- Argentina
- Prior art keywords
- autoimmune diseases
- useful
- pharmaceutical composition
- improving therapy
- reumatoid arthritis
- Prior art date
Links
- 208000023275 Autoimmune disease Diseases 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 4
- 206010003246 arthritis Diseases 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 229940125721 immunosuppressive agent Drugs 0.000 abstract 2
- 239000003018 immunosuppressive agent Substances 0.000 abstract 2
- 206010067484 Adverse reaction Diseases 0.000 abstract 1
- ANMATWQYLIFGOK-UHFFFAOYSA-N Iguratimod Chemical compound CS(=O)(=O)NC1=CC=2OC=C(NC=O)C(=O)C=2C=C1OC1=CC=CC=C1 ANMATWQYLIFGOK-UHFFFAOYSA-N 0.000 abstract 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 abstract 1
- 230000006838 adverse reaction Effects 0.000 abstract 1
- 229950003909 iguratimod Drugs 0.000 abstract 1
- 229960000485 methotrexate Drugs 0.000 abstract 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 abstract 1
- 229960005205 prednisolone Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Toxicology (AREA)
- Pulmonology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Un método para utilizar iguratimod o una sal del mismo y uno o más agentes inmunosupresores en combinación es útil como un método para tratar enfermedades autoinmunes con una reacción adversa reducida. Una composición farmacéutica, que contiene estos componentes es útil para el tratamiento de enfermedades autoinmunes. El método y la composición farmacéutica de la presente son útiles para el tratamiento de enfermedades autoinmunes más severas. Reivindicación 7: La composición farmacéutica de acuerdo con cualquiera de las reivindicaciones 1 a 5, caracterizado porque el agente inmunosupresor es metotrexato o prednisolona.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011188011 | 2011-08-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR087748A1 true AR087748A1 (es) | 2014-04-16 |
Family
ID=47756311
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP120103216A AR087748A1 (es) | 2011-08-30 | 2012-08-30 | Metodo para mejorar la terapia de enfermedades autoinmunes tales como artritis reumatoide |
Country Status (10)
Country | Link |
---|---|
US (1) | US9421186B2 (es) |
EP (1) | EP2752190B1 (es) |
JP (1) | JP6088429B2 (es) |
KR (1) | KR101722432B1 (es) |
CN (1) | CN103826624A (es) |
AR (1) | AR087748A1 (es) |
BR (1) | BR112014002407A2 (es) |
RU (1) | RU2611341C2 (es) |
TW (1) | TWI606826B (es) |
WO (1) | WO2013031831A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI2929880T1 (sl) | 2013-07-18 | 2016-12-30 | Toyama Chemical Co., Ltd. | Zdravilo za bolezni na osnovi inhibitornega efekta faktorja inhibicije migracije makrofagov |
CN106806353B (zh) * | 2015-12-02 | 2021-04-27 | 江苏先声药业有限公司 | 艾拉莫德缓释胶囊及其制备方法 |
CN107456454A (zh) * | 2016-06-06 | 2017-12-12 | 先声药业有限公司 | 一种预防或治疗炎性疾病的药物组合物 |
CN107582537A (zh) * | 2017-09-26 | 2018-01-16 | 江苏正大清江制药有限公司 | 一种艾拉莫德的药物组合物 |
CN114028540B (zh) * | 2021-11-26 | 2023-10-17 | 海南鑫开源医药科技有限公司 | 一种具有镇痛作用的组合物、微针贴片及其制备方法以及应用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69427907T2 (de) | 1993-04-09 | 2002-04-04 | Toyama Chemical Co. Ltd., Tokio/Tokyo | Immunomodulator, zelladhäsionsinhibitor und mittel zur behandlung und vorbeugung von autoimmunerkrankungen |
US5822755A (en) * | 1996-01-25 | 1998-10-13 | International Business Machines Corporation | Dual usage memory selectively behaving as a victim cache for L1 cache or as a tag array for L2 cache |
DE19839566C2 (de) * | 1998-08-31 | 2002-01-17 | Fumapharm Ag Muri | Verwendung von Fumarsäurederivaten in der Transplantationsmedizin |
WO2005123193A2 (en) * | 2004-06-17 | 2005-12-29 | Osteologix A/S | Treatments comprising strontium for rheumatic and arthritic diseases and pain |
EP1940382A2 (en) * | 2005-10-07 | 2008-07-09 | Aditech Pharma AB | Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders |
EP2135610A1 (en) * | 2008-06-20 | 2009-12-23 | Laboratorios Almirall, S.A. | Combination comprising DHODH inhibitors and methotrexate |
US20100158905A1 (en) | 2008-12-19 | 2010-06-24 | Nuon Therapeutics, Inc. | Combination therapy of arthritis with tranilast |
EP2210615A1 (en) | 2009-01-21 | 2010-07-28 | Almirall, S.A. | Combinations comprising methotrexate and DHODH inhibitors |
-
2012
- 2012-08-29 BR BR112014002407A patent/BR112014002407A2/pt not_active Application Discontinuation
- 2012-08-29 WO PCT/JP2012/071840 patent/WO2013031831A1/ja active Application Filing
- 2012-08-29 JP JP2013531358A patent/JP6088429B2/ja active Active
- 2012-08-29 CN CN201280041819.1A patent/CN103826624A/zh active Pending
- 2012-08-29 TW TW101131271A patent/TWI606826B/zh active
- 2012-08-29 KR KR1020147007979A patent/KR101722432B1/ko active IP Right Grant
- 2012-08-29 RU RU2014112210A patent/RU2611341C2/ru active
- 2012-08-29 EP EP12827070.9A patent/EP2752190B1/en active Active
- 2012-08-29 US US14/241,655 patent/US9421186B2/en active Active
- 2012-08-30 AR ARP120103216A patent/AR087748A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
US20150080356A1 (en) | 2015-03-19 |
JPWO2013031831A1 (ja) | 2015-03-23 |
US9421186B2 (en) | 2016-08-23 |
EP2752190B1 (en) | 2021-03-03 |
BR112014002407A2 (pt) | 2017-02-21 |
KR20140068098A (ko) | 2014-06-05 |
TWI606826B (zh) | 2017-12-01 |
JP6088429B2 (ja) | 2017-03-01 |
RU2611341C2 (ru) | 2017-02-21 |
RU2014112210A (ru) | 2015-10-10 |
KR101722432B1 (ko) | 2017-04-04 |
EP2752190A4 (en) | 2015-06-24 |
WO2013031831A1 (ja) | 2013-03-07 |
TW201313229A (zh) | 2013-04-01 |
CN103826624A (zh) | 2014-05-28 |
EP2752190A1 (en) | 2014-07-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GT201700072A (es) | Composiciones y métodos de uso para tratar trastornos metabólicos | |
PE20181295A1 (es) | Metodos y composiciones para tratar afecciones asociadas a una respuesta inflamatoria anomala | |
AR101740A1 (es) | Terapia de combinación y composiciones | |
CL2017003073A1 (es) | Inhibidores de tirosina-cinasas | |
MX2023009483A (es) | Anticuerpos monoclonales para usarse para el tratamiento de sinucleinopatia. | |
CR20140108A (es) | Compuesto de ciclopropanoamina | |
BR112017007975A2 (pt) | composições e métodos para o tratamento de disfunção das glândulas meibomianas | |
CL2011000668A1 (es) | Compuestos derivados de pirazolopiridina; proceso de preparacion; composicion farmaceutica y uso en el tratamiento de enfermedades tales como artritis reumatoide, psoriasis, esclerosis multiple, entre otras. | |
AR082340A1 (es) | Metodos y composiciones para la terapia del cancer de higado | |
CL2015002443A1 (es) | Péptidos y composiciones para el tratamiento del daño articular | |
CL2009000650A1 (es) | Compuestos derivados de amino-pirazina, inhibidores de cinasa-pi 3; composicion farmaceutica; y uso para el tratamiento de condiciones inflamatorias o alérgicas, tales como enfermedades respiratorias, artritis reumatoide, colitis ulcerativa, entre otras | |
BR112014031421A2 (pt) | composições para tratamento de câncer e métodos para produção das mesmas | |
UY36075A (es) | Derivados de tubulisina | |
AR087748A1 (es) | Metodo para mejorar la terapia de enfermedades autoinmunes tales como artritis reumatoide | |
ECSP14000606A (es) | Agentes inductores de la apoptosis que pueden usarse para tratar el cáncer y las enfermedades inmunes y autoinmunes | |
BR112017007063A2 (pt) | ?composições e métodos para o tratamento de insônia? | |
BR112016027871A2 (pt) | composição para melhorar a memória, a função de aprendizado e/ou função cognitiva | |
MX2015016100A (es) | Inhibidores de criopirina para prevenir y tratar la inflamacion. | |
CO2017001025A2 (es) | Métodos y composiciones para tratar la obesidad, prevenir el aumento de peso, promover la pérdida de peso, promover el adelgazamiento o tratar o prevenir el desarrollo de la diabetes | |
CL2018000597A1 (es) | Métodos para tratar enfermedades inflamatorias | |
CR20170085A (es) | Terapia adjuntiva con 25-hidroxi vitamina d | |
ECSP16075416A (es) | Anticuerpos de il-21 | |
BR112015018360A2 (pt) | terapia de combinação para o tratamento de pneumonia nosocomial | |
CO2017002312A2 (es) | Compuestos bicíclicos sustituidos | |
AR094851A1 (es) | COMPUESTOS BICíCLICOS COMO AGONISTAS DE S1P₁ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |